Hereditary haemorrhagic telangiectasia: a clinical and scientific review

The autosomal-dominant trait hereditary haemorrhagic telangiectasia (HHT) affects 1 in 5–8000 people. Genes mutated in HHT (most commonly for endoglin or activin receptor-like kinase (ALK1)) encode proteins that modulate transforming growth factor (TGF)-β superfamily signalling in vascular endothelial cells; mutations lead to the development of fragile telangiectatic vessels and arteriovenous malformations. In this article, we review the underlying molecular, cellular and circulatory pathobiology; explore HHT clinical and genetic diagnostic strategies; present detailed considerations regarding screening for asymptomatic visceral involvement; and provide overviews of management strategies.

In brief

- Autosomal dominant.
- Commonly results from mutations in endoglin (HHT1) or ACVRL1 (HHT2).
- Rarely due to mutations in Smad4, or other genes.
- Known disease genes involved in TGF-β superfamily signalling.
- Marked intrarafamilial variation.
- Many patients experience only nosebleeds and telangiectasia, and have a normal life span.
- Approximately one-third of patients have chronic anaemia, with gastrointestinal bleeding increasing with age.
- Asymptomatic arteriovenous malformations occur in pulmonary (~50%), hepatic (~30%), cerebral (~10%) and spinal (~1%) circulations.
- Common AVM complications include stroke (ischaemic and haemorrhagic) and brain abscess.
- Rarer HHT complications include deep venous thromboses; symptomatic liver disease requiring liver transplantation; severe pulmonary hypertension; pregnancy-related death; and spinovascular accidents.

Introduction

The vascular disorder hereditary haemorrhagic telangiectasia (HHT) affects 1 in 5–8000, and is inherited as an autosomal-dominant trait. HHT disease-causing genes encode proteins that modulate transforming growth factor (TGF)-β superfamily signalling in vascular endothelial cells. Genetic testing for endoglin (HHT type 1), activin receptor-like kinase (ALK1) (HHT type 2) and Smad4 (HHT in association with juvenile polyposis (JPHT)) is available; further genes are predicted at loci identified by linkage analyses on chromosomes 5 (HHT3) and 7 (HHT4) (Table 1). Although HHT predominantly manifests as a heterozygous condition, several studies investigating children with two affected parents support in utero or infantile homozygous lethality in HHT.

HHT gene mutations lead to the development of abnormal vascular structures, which range from dilated microvessels to large arteriovenous malformations (AVMs) measuring several centimeters in diameter (Figure 1). These occur at specific sites in systemic and pulmonary circulations (Figure 2). Fragile walls and turbulent blood flow render these vessels more prone to haemorrhage than normal vessels. However, for pulmonary and hepatic AVMs, it is the consequences of arteriovenous shunting that lead to most clinical features (Table 2). Complications commonly occur from previously silent AVMs, and complications can be prevented if AVMs are recognised and treated. Asymptomatic screening and treatment programmes...
form major components of HHT management. Useful recent reviews include those by Abdalla et al.,12 Bayrak-Toydemir et al.,13 Begbie et al.14 and by Sabba et al.15

Clinical overview

HHT was first described as a familial disease characterised by anaemia, severe recurrent nosebleeds and gastrointestinal blood loss.16,17 There was early recognition of HHT-affected individuals developing abnormal vascular structures at other sites, particularly AVMs of the pulmonary,18 hepatic19 and cerebral20 circulations. The majority of HHT patients will be affected by AVMs in at least one of these sites, with AVMs usually remaining silent.21 More recently, the HHT disease spectrum has expanded further to encompass pulmonary hypertension (two forms pre-dominate in HHT), juvenile polyposis, a prothrombotic state and potential immune dysfunction (see Table 2 for references).

HHT presentation patterns are highly variable even within families. Spontaneous recurrent nosebleeds are the most common and usually earliest clinical manifestation of HHT, often commencing before school age. Telangiectases of the skin and buccal mucosa typically present from about the third decade of life, and increase with age. Recurrent haemorrhage from the gastrointestinal tract is a feature of later years in 15–20% of individuals.22 Major complications of HHT include severe anaemia from chronic nasal and gastrointestinal haemorrhage; stroke (ischaemic and brain abscess from pulmonary AVMs; haemorrhagic from cerebral AVMs); deep venous thromboses, and in rarer cases, symptomatic liver disease requiring liver transplantation; severe pulmonary hyper-

<table>
<thead>
<tr>
<th>HHT</th>
<th>OMIM</th>
<th>HHT type</th>
<th>Chromosome</th>
<th>Approved gene symbol</th>
<th>Protein</th>
<th>Sequence accession IDs</th>
<th>Earlier symbols</th>
<th>Aliases</th>
</tr>
</thead>
<tbody>
<tr>
<td>HHT1 #187300</td>
<td>Type 1</td>
<td>9</td>
<td>ENG</td>
<td>Endoglin</td>
<td>AF035753</td>
<td>ORW1, ORW</td>
<td>HHT1, END, CD10S</td>
<td>HHT1, END, CD10S</td>
</tr>
<tr>
<td>HHT2 #600376</td>
<td>Type 2</td>
<td>12</td>
<td>ACVR1</td>
<td>Activin receptor-like kinase ALK-1</td>
<td>L17075</td>
<td>ACVRK1, ORW2</td>
<td>HHT2, ALK1</td>
<td>HHT2, ALK1</td>
</tr>
<tr>
<td>HTJP #175050</td>
<td>HTJP</td>
<td>18</td>
<td>SMAD4</td>
<td>Smad 4</td>
<td>NM 005399</td>
<td>DPC4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HHT3 %601101</td>
<td>Type 3</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HHT4 %610655</td>
<td>Type 4</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 1 HHT images. (a) Fingertip and (b) gastrointestinal telangiectasia (largest examples arrowed). (c) × 40 magnification of oral telangiectasia in an individual with HHT compared with control (inset). Note ruptured wall denoted by arrow. (d) Pulmonary AVM (arrowed) pre (i) and post (ii) embolisation: Angiograms are presented courtesy of Dr James Jackson.
tension; pregnancy-related death, and spinovascular accidents (see Table 2). Most HHT-affected individuals, however, will not have life-limiting consequences from their HHT. Presymptomatic AVM screening programmes highlight the fact that before screening, the majority of affected individuals are unaware of their HHT diagnosis. The goal of HHT management is to optimise the overall outcome of affected individuals, without raising excessive alarm regarding vascular lesions that may be of little consequence. Symptomatic patients with active medical problems because of their HHT deserve review by informed specialised services. For people with HHT who are well, the focus is on education (including recently published recommendations regarding dental care and pregnancy management) and presymptomatic screening programmes. Exact clinical management regimes differ between countries, predominantly because of differing healthcare practices (see Acknowledgements section tab (^)).

Molecular and genetic basis of the disease
Mutated genes and new loci
Three HHT disease-causing genes have been identified to date (Table 1). HHT type 1 results from mutations in ENG encoding endoglin (Figure 3a); HHT type 2 results from mutations in ACVRL1 encoding ALK1 (Figure 3b), and HHT in association with juvenile polyposis (JPHT) results from mutations in MADH4 (Figure 3c). There are at least two further unidentified genes that can cause classical HHT, HHT3 mapped to chromosome 5q between D5S2011 and D5S2490 (Figure 3c) and HHT4 on chromosome 7p between D7S2252 and D7S510 (Figure 3d).

Distribution and frequency of gene mutations
The majority of HHT patients (>80%) will have mutations in either ENG or ACVRL1, ENG mutations being more common (61%) than ACVRL1 mutations (37%) or MADH4 (2%). There is a geographical variation, with both North

---

**Figure 2** Circulatory explanation of HHT phenotypes. (a) Schematic of systemic and pulmonary circulations showing capillary beds in which HHT telangiectasia and AVMs occur. Note the pulmonary post capillary veins are in direct communication with the left atrium, and the portal vein which drains from the gastrointestinal tract to liver acinus. (b) Illustration of two separate pathologies resulting in severe pulmonary hypertension in two women with HHT (reported in Shovlin et al). Note case 1 has markedly elevated intrinsic pulmonary vascular resistance, whereas this is near-normal in case 2, who has hepatic AVM-associated high output cardiac failure characterised by elevated cardiac output, cardiac index (not shown), and left atrial pressure.
American and European series showing either ACVRL1 predominance (USA; 31 European32,33) or an ENG bias (USA,34 European35,36). It is therefore not clear whether this reflects the referral practice of HHT centres or genuine geographical variation.

More than 600 different mutations have been found in ENG or ACVR in HHT families (see http://www.hhtmutation.org). Neither gene displays a common mutation, and the majority of mutations have been reported only once. All types of mutations are found in ENG and ACVRL1, including deletions, insertions, missense, nonsense and splice site (Figure 3). The JPHT mutations found to date are in the last four exons of Smad4 (exons 8–11); mutation types include missense, nonsense and frameshift, with a high incidence of de novo mutations.29,30

Genotype–phenotype relationships
Recent large series support early observations, finding pulmonary and cerebral AVMs more common in HHT1 (ENG mutations), and hepatic AVMs more common in HHT2 (ACVRL1 mutations).31–36 Although there was an initial suggestion that overall severity of disease is greater in HHT1 than in HHT2,37 this study predated the

Table 2 HHT Clinical features and management overview

<table>
<thead>
<tr>
<th>Feature</th>
<th>%</th>
<th>Haem.</th>
<th>Other complications</th>
<th>Management if symptomatic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Curacao criteria</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasal telangiectasia</td>
<td>90</td>
<td>++++</td>
<td>Iron deficiency anaemia</td>
<td>Iron +/- – transfusions for anaemia. Nasal humidification; packing in emergencies. ENT: laser; surgery; embolisation; Systemic: oestrogen–progesterone, antifibrinolytics*</td>
</tr>
<tr>
<td>Mucocutaneous telangiectasia</td>
<td>80</td>
<td>++</td>
<td></td>
<td>Laser or other ablation therapies</td>
</tr>
<tr>
<td>Gastrointestinal telangiectasia</td>
<td>20</td>
<td>+++</td>
<td>Iron deficiency anaemia</td>
<td>Iron +/- – transfusions for anaemia. Gastroenterology: Repeated laser therapy; surgery or embolisation for emergency control</td>
</tr>
<tr>
<td>Pulmonary AVMs</td>
<td>50</td>
<td>+</td>
<td>Right-to-left shunt: dyspnoea, stroke/TIA; brain abscess; migraine; decompression illness</td>
<td>Embolisation Dental hygiene and prophylactic antibiotics Caution against scuba diving</td>
</tr>
<tr>
<td>Cerebral AVMs</td>
<td>10</td>
<td>++</td>
<td>Space occupying lesion +/- vascular steal: headache, fit</td>
<td>Cerebral MRI. Refer to neurology for multidisciplinary evaluation of risk–benefits of treatment in an experienced centre</td>
</tr>
<tr>
<td>Hepatic AVMs</td>
<td>≥ 30</td>
<td></td>
<td>Left to right shunt: high output cardiac heart failure; pulmonary hypertension. Hepato-portal shunt: portal hypertension. Porto-hepatic shunt: biliary ischaemia, encephalopathy</td>
<td>Refer to specialized hepatology services for intensive medical management: liver transplantation is the treatment of choice if symptoms fail to respond to medical treatment</td>
</tr>
<tr>
<td>Spinal AVMs</td>
<td>1</td>
<td>++</td>
<td>Pain, asymmetric growth</td>
<td>Spinal MRI. Refer to neurology for multidisciplinary evaluation of risk–benefits of treatment in an experienced centre</td>
</tr>
</tbody>
</table>

Non-criterion manifestations

<table>
<thead>
<tr>
<th>Feature</th>
<th>%</th>
<th>Haem.</th>
<th>Other complications</th>
<th>Management if symptomatic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Juvenile polyposis (Smad4)</td>
<td>&lt; 1</td>
<td></td>
<td>Haemorrhage, malignancy</td>
<td>Refer to gastroenterology, and follow national surveillance guidelines such as</td>
</tr>
<tr>
<td>Pulmonary hypertension</td>
<td>&lt; 2</td>
<td></td>
<td>Dyspnoea, right heart failure</td>
<td>Refer to cardiorespiratory; Exclude hepatic AVMs; if present, consider liver transplant As per national guidelines, eg, 10</td>
</tr>
<tr>
<td>Prothrombotic state</td>
<td></td>
<td></td>
<td>Deep venous thrombosis, pulmonary emboli</td>
<td></td>
</tr>
<tr>
<td>Immune dysfunction</td>
<td></td>
<td></td>
<td>Uncertain</td>
<td></td>
</tr>
</tbody>
</table>

%: Estimated prevalence across all age groups. Haem., haemorrhage frequency scale 0 to ++++. *Ensure not prothrombotic first.9 Further agents are undergoing clinical evaluation, particularly, in the setting of severe gastrointestinal and nasal haemorrhage. Shunt anatomy: right-to-left: pulmonary artery to pulmonary vein, left-to-right: hepatic artery to hepatic vein, Hepato-portal: hepatic artery to portal vein; Porto-hepatic: portal vein to hepatic vein.
recognition of pulmonary hypertension, and there was no difference in the 90-month mortality in a later series.^{36}  
Pulmonary hypertension^{38} and juvenile polyposis^{29} are recognised as part of the spectrum of HHT for particular families. As illustrated in Figure 2b, pulmonary hypertension is not a single disease entity and can result from multiple secondary causes in HHT. The pure pulmonary arterial hypertension (PAH) phenotype seen in patients with HHT is indistinguishable from PAH in the general population due to mutations in the related BMPRII (Figure 4). Juvenile polyposis (JP) seen in HHT patients with Smad4 mutations is indistinguishable from JP in the general population most commonly due to mutations in BMPR1A, which encodes another related protein (ALK3 in Figure 4). In HHT, pulmonary artery hypertension and JP were initially considered attributable solely to ACVRL1 and Smad4 mutations, respectively. There are rare reports of both pulmonary artery hypertension and JP associated with ENG missense mutations. Further evaluation is needed to determine whether these ENG sequence variations are HHT disease-causing or benign variants.

These genotype–phenotype correlation studies suggest that, although normal function of the gene products of ENG, ACVRL1 and MADH4 are required to prevent the development of an HHT-like phenotype, there are likely to be differences in the normal requirements for the three proteins in different vascular beds and cell types.

**Biology of the disease**

Phenotypic considerations, expression analysis of mutant endoglin and ALK1 proteins, and HHT-like phenotypes in heterozygous mice implicate haploinsufficiency of the respective protein as the cause of HHT1 and HHT2.^{12} Dominant negative mutations in endoglin can be generated, but may cause different phenotypes; for example, truncated soluble endoglin is associated with the non-HHT phenotype of pre-eclampsia.^{39}

The genes mutated in HHT encode proteins involved in TGF-β superfamily signalling; perturbation of these signalling pathways is therefore implicated in the pathogenesis of HHT. Superfamily ligands such as TGF-βs, BMPs, activins, nodals, nodals, GDFs and inhibins normally regulate diverse cellular functions, such as cellular survival, proliferation and differentiation, by binding to a heteromeric complex of type I and type II transmembrane serine/
threonine kinase receptors (Figure 4). Signalling can be propagated through Smad-dependent and Smad-independent pathways. In Smad-dependent pathways, in which all three known HHT gene products function, ligand binding activates a TGF-β type II receptor, which in turn phosphorylates and activates a type I receptor. The type I receptor subsequently phosphorylates and activates receptor associated (R)-Smads (Smads 1, 2, 3, 5 and/or 8), which bind to Smad4 and translocate to the nucleus, where they influence transcriptional activation with co-activators and co-repressors. Inhibitory Smads (Smad6/7) target R-Smads for degradation and provide a negative feedback loop for this pathway. In most cell types, TbRII signalling transmits through ALK5 (TbRI) via Smad2/3 pathways. In endothelial cells, however, TbRII signalling can also be propagated through ALK1 via Smad1/5/8 pathways. The ALK1 ligand has been unknown for a long time, but recently it was shown that BMP9 and BMP10 are specific ALK1 ligands that can also bind endoglin (Figure 4).

Several series of HHT animal models are now described. Null mice for Eng and Activin receptor-like 1 (Acvr1l1) die between E10.5–11.5 because of gross vascular and cardiac defects comparable with multiple other null mice, potentially reflecting aberrant placental vascular development. Heterozygous mice develop variable, but more HHT-specific, features including nosebleeds, telangiectasia, dilated vessels and AVMs. Conditional LoxP knockout alleles have been generated for all three HHT genes and for ALK1, result in a model in which HHT-like vascular malformations occurred in a consistent and predictable manner. These and other models are under active study.

Current HHT models

What causes the pathogenesis of HHT? This has been a controversial topic for many years and remains unresolved, in part because of the non-uniformity of the disease process in affected vascular beds. The precise sequence of events remains to be determined, but most likely involves aberrant endothelial cell responses to TGF-β/BMP signalling in specific settings. A favoured model has been generated from data focussing on the two TbRII-associated type I receptors (ALK5 and ALK1), suggesting that the endothelial state depends on the predominant type I receptor used, and that abnormal vasculature in HHT resulted from a perturbation of this balance. This balance model has been both challenged and supported by recent data, and remains a helpful tool in clarifying signalling pathway interrelationships.

For example, endoglin and ALK1 are involved in angiogenesis, the process in which new blood vessels are formed from pre-existing ones. During angiogenesis, mural cells (smooth muscle cells, pericytes) detach, and brief periods of endothelial cell activation, proliferation and migration are co-ordinated with controlled proteolytic remodelling of the basement membrane and extracellular matrix, expression of endothelial cell survival factors, and recruitment of mural cells to stabilise the nascent blood vessels. There are complex context-dependent biological activities of the HHT gene products in these processes such that over-expression of constitutively active ALK1 or under-expression of endoglin can each either promote or inhibit specific endothelial cell responses according to the experimental conditions. However, evidence suggests that
endoglin and ALK1 responses promote opposing endothelial cell responses (such as proliferation, migration) to ALK5, and that the ratio of ALK5 and ALK1 activation by TGF-β superfamily ligands can influence whether pro- or anti-angiogenic genes are predominantly expressed.\textsuperscript{49}

Management
Diagnostic approaches

Clinical diagnosis of HHT The Curacao criteria, published in 2000,\textsuperscript{50} remain the mainstay of HHT clinical diagnosis. A definite diagnosis of HHT is made in the presence of at least three separate manifestations:

- spontaneous recurrent nosebleeds;
- mucocutaneous telangiectasia (multiple at characteristic sites: fingertip pulps, lips, oral mucosa or tongue);
- visceral involvement (gastrointestinal, pulmonary, hepatic, cerebral or spinal AVM);
- family history: a first-degree relative affected according to these criteria

Family history plus one criterion When reviewing individuals from HHT families, clinicians are often faced with individuals with only one additional diagnostic criterion. In clinical practice, if the non-familial criterion is a visceral AVM, which would be very rare in the general population, the diagnosis of HHT is essentially confirmed. This is not the case for nosebleeds, which are common in the general population, or non-florid telangiectasia, which can be readily confused with non-HHT pathologies. For research and epidemiological studies, the labels of possible or suspected HHT should be used for all individuals with only two diagnostic criteria.\textsuperscript{50}

Family history only Although HHT is likely to present with nosebleeds during childhood, the condition cannot be excluded on clinical grounds even at the age of 30–40 years. For an apparently unaffected child of an HHT-affected parent, clinical data on age-related penetrance in European HHT populations allow estimations of the probability of HHT-affected status ranging from 0.5 at 0 years; 0.22 at 16 years; 0.05 at 40 years and 0.01 at 60 years.\textsuperscript{22,51,52} Possible HHT\textsuperscript{*} can be added to the medical records of such individuals.

Molecular diagnosis Genetic testing for endoglin, ALK1/ACVRL1 and Smad4 is available and can confirm the diagnosis for the family, and confirm or refute the diagnosis in family members. Strategies to use genetic tests vary between units.

For patients with definite clinical HHT, molecular testing is not required to confirm their diagnosis, but may assist management of other family members. Mutations are not found in about 20% of HHT families; hence, failure to detect a causative HHT mutation in a family does not exclude HHT. Not all ENG/ACVRL1/Smad4 gene sequence variations in HHT families are disease-causing (http://www.hhtmutation.org); in those cases in which it is difficult to distinguish from incidental polymorphisms, assessment of co-segregation in a distant affected relative may be helpful.

Genetic testing is most helpful in the settings of

- a potentially unaffected family member in whom the diagnosis of HHT cannot be excluded clinically;
- a patient with suggestive, but not confirmatory, clinical features of HHT, in whom a positive test would be diagnostic.

Other genetic counselling issues

- The hallmark of clinical HHT is the variability between different affected members of the same HHT family. Nevertheless, there are genotype–phenotype correlations related to the causative HHT gene mutation, and as-yet unidentified genetic modifiers
- Prenatal diagnosis is technically feasible and chosen by some families. Generally, however, there has been little interest in, or use of, prenatal molecular diagnosis for HHT in view of the longevity and paucisymptomatic state of most HHT patients (\textsuperscript{\textasteriskcentered}).
- At present, a positive molecular diagnosis does not modify recommended screening or management, except in the setting of HHT-affected individuals with a family history of gastrointestinal polyps/malignancy; identification of a Smad4 mutation would lead to institution of gastrointestinal screening programmes.

Clinical work-up

The basic work-up approach for suspected HHT patients is illustrated in Figure 5. After a clinical evaluation, including a detailed family history, emphasis is placed on:

- ensuring that patients with a particular problem are reviewed by an organ-specific specialist aware of HHT issues (details of management are beyond the scope of this text, but outlined within Table 2);
- screening for asymptomatic AVMs according to local or regional practice (see below);
- formalizing the diagnosis of HHT, which may require molecular testing;
- providing information and opportunity for follow-up and family screens.

Screening

The medical justification for screening regimes in asymptomatic individuals from the HHT population

*European Journal of Human Genetics*
centres on the degree of danger posed by silent AVMs (as opposed to symptomatic AVMs), the safety/tolerability of the diagnostic tool, the advantages offered by the correct diagnosis in terms of patient management and follow-up, and the safety of effective treatments. Risk–benefit evaluations are then performed to determine whether the detection and treatment of the asymptomatic AVM is likely to carry overall positive health benefits for the patient.

Where risk–benefit considerations are less clear cut, different interpretations are observed, and generally reflect the overall healthcare practices of particular countries and cultures. To reflect these differing practices and the evolving nature of recommendations as new data regarding natural history and treatment safety/efficacy become available, Figure 5 presents only limited data regarding specific particular screening and management regimes. Detailed considerations are presented below.

Pulmonary AVMs
Pulmonary AVMs are usually silent at the time of PAVM-induced strokes and brain abscess, can be diagnosed at low risk and have an effective and safe treatment with embolisation shown to reduce or abolish neurological risks. Hence, detection and treatment of asymptomatic pulmonary AVMs is recommended worldwide for adults.

For highly sensitive screening tests, the choice lies between thoracic CT scans and contrast echocardiography (CE). Use of either test means that very few pulmonary PAVMs will be missed out in an HHT population, whereas chest x-rays, blood oxygen levels and right-to-left shunt measurements are insufficiently sensitive to exclude pulmonary AVMs. Both CT and CE also allow for the detection of severe pulmonary hypertension, which is a relative contraindication to embolisation.53

Many specialised units use a multistep-screening programme using CE as a first line screen. After intravenous injection of contrast or microbubbles, which should be removed by the normal pulmonary capillary bed, right-to-left shunting through pulmonary AVMs results in the appearance of microbubbles on the left side of the circulation. Arrival is usually delayed compared with intracardiac shunts, with bubbles arriving after 3–10 cardiac cycles associated with pulmonary AVMs.54 Shunt severity may be graded by the number of microbubbles appearing on a single frame. Higher grade shunts (>20–30 microbubbles per frame) have higher positive predictive values.54–56 After a positive study, patients proceed to thoracic CT scans to determine anatomical features and suitability for embolisation treatment.

Discussion continues regarding the degree to which a negative screen (by CT or CE) can be used to rule out small PAVMs, which may nevertheless carry risks of dental bacteraemias and decompression illness during scuba diving. The current practice at our institution is to provide recommendations regarding dental hygiene to all HHT patients, and to refer divers for specialist advice and evaluation.

Cerebral AVMs
Screening of asymptomatic patients for cerebral AVMs is recommended in many countries, but remains controversial in others (*): Cerebral haemorrhages in HHT patients are usually life-changing and may be fatal. Conversely, most HHT-related cerebral AVMs will never bleed, and
investigation and treatments carry risks. Both sets of considerations differ with the precise anatomy and location of the AVM. Other important considerations are that cerebral AVMs are more common in HHT1 families and that the lifelong risk of haemorrhage is higher for younger patients because of their longer predicted lifespan.

In the UK, we have followed the interpretation articulated by the late Pierre Lasjaunias that risk–benefit considerations for asymptomatic cerebral AVMs are usually not interpreted in favour of treatment because the risks of intervention are too high for the low risk of haemorrhage. Thus, up to 10% of screened individuals would be faced with the identification of cerebral AVMs for which no treatment or management options would be currently recommended. At our institution, we discuss these considerations openly with the patient and, generally, cerebral MRI is not performed. However, for any individual with a family member who has had a cerebral haemorrhage, or in whom there is any concern regarding cerebral symptoms, a cerebral MRI is recommended to rule out a chance inheritance of familial aneurysms (which carry a higher risk of haemorrhage) or presence of an unstable, symptomatic cerebral AVM.

Hepatic AVMs
Screening considerations for hepatic AVMs in asymptomatic individuals differ from those for cerebral and pulmonary AVMs, as hepatic AVM management is directed towards symptomatic patients who receive intensive medical treatment, with liver transplantation (which is effective in HHT) reserved for non-responders. However, as there is a totally non-invasive and effective screening tool (Doppler US), and because a correct diagnosis can help to clarify the diagnosis of HHT and improve subsequent patient management, screening of asymptomatic individuals for hepatic AVMs has been recommended.

Special considerations in pregnancy
The overwhelming majority of pregnancies in women with HHT proceed normally, but there are small risks of life-threatening maternal complications; in a recent series of 484 pregnancies, 1.02% (95% confidence intervals 0.13, 1.92%) resulted in a major PAVM bleed; 1.24% (0.25, 2.23%) in stroke (not all were HHT-related); and 1.00% (0.13, 1.92%) in maternal death. In British obstetric terminology, this renders HHT pregnancies high risk for greater obstetric medical review than recommended for low-risk pregnancies.

The data for and against screening asymptomatic women during pregnancy for pulmonary, cerebral or spinal AVMs were discussed in detail in the paper. The Anglo-French authors’ recommendations for their obstetric healthcare systems were, in the absence of symptoms, to defer pulmonary AVM screens, only perform cerebral imaging if warranted by family history and to consider spinal MRI in those cases in which the possibility of spinal AVMs would lead obstetric anaesthetists to withhold epidural analgesia. There are strong opinions in other countries that asymptomatic women should be screened and treated for pulmonary AVMs during pregnancy. As a result, there are different practices among countries.

Children
Occasionally, children from HHT families have major complications from HHT, but the majority have healthy childhoods, with or without nosebleeds, and usually without anaemia. AVMs may be present (cerebral AVMs usually develop perinatally and can bleed in childhood; pulmonary AVMs may develop in the pre-pubertal period, but complications in asymptomatic children are extremely rare). There are few data regarding dedicated risk–benefit considerations for the paediatric population, particularly regarding their increased susceptibility to diagnostic radiation-induced morbidity from CT scans and angiography. The ethics of screening an asymptomatic child, who is too young to give consent and will likely not understand the implications of testing, also need to be carefully considered before proceeding. Institutions therefore differ in their screening regimes. Practice ranges from screening for all manifestations of HHT to deferring screening in most asymptomatic children until post-puberty, unless dictated otherwise by family history.

Treatment and care
Brief details of medical management are given in Table 2 for clinicians. Additional information is warranted for several points for clinicians and patients alike. Our practice is to provide this general advice for the whole family, with particular focus on individual patients according to the aspects of HHT known to affect them. This is particularly important when the presence of HHT would modify general clinical protocols for management of common conditions such as stroke, and prophylaxis against deep venous thrombosis (see below).

Anaemia
It is unusual to be able to abolish nasal and gastrointestinal bleeding. Prevention and management of anaemia becomes paramount in at least one-third of HHT patients. Dietary advice for foods containing iron, and identification of oral iron preparations that suit the individual are important steps to reduce the need or frequency of transfusions or iron infusions required for severely affected individuals.

Pulmonary AVMs
Irrespective of size or symptoms, these carry risks of paradoxical embolic stroke and brain abscess, which can be reduced or abolished by embolisation. Owing to brain
abscess links with dental microorganisms, scrupulous dental hygiene and antibiotic prophylaxis at the time of dental procedures have been recommended, and this advice has been recently confirmed by senior British dentists, recognizing the differences between HHT/PAVM patients, and individuals at risk of infective endocarditis, for whom prophylaxis was withdrawn.  

**Stroke advice**

HHT-affected families should be aware that in the event of stroke-like features, their doctors may need to be alerted to their three potential stroke types (haemorrhagic, ischaemic and brain abscess), leading to modification of local stroke-management protocols.

**Liver evaluations**

Hepatic AVMs commonly lead to asymptomatic abnormalities in biochemical markers of cholestasis, and the benign condition of focal nodular hyperplasia. These are of little clinical importance, but could potentially result in unnecessary diagnostic tests. HHT patients should be advised to exclude liver biopsy, unless imaging has excluded hepatic AVMs.  

**Deep venous thrombosis prophylaxis**

Prophylaxis against deep venous thromboses is often modified or withheld for patients with haemorrhagic conditions such as HHT. Recent data highlight that HHT-affected individuals are at risk for thrombotic events, and should be considered for full prophylaxis at appropriate times, particularly in periods after a pulmonary AVM-induced brain abscess.  

**Pregnancy**

Irrespective of earlier screening and treatment, obstetricians should be alerted to the presence of HHT for all women with HHT. Any haemoptysis or sudden severe dyspnoea should be considered a potential emergency, prompting immediate hospital admission.  

**Conclusion**

The diagnosis of HHT has been facilitated with the identification of several disease-causing genes, but management of both symptomatic and asymptomatic individuals remains highly challenging for experienced specialists. Discussion of risks and complex risk–benefit analyses need to be handled sensitively and appropriately for age, family, cultural and national background. Major clinical and research hurdles remain if we are to more closely predict and prevent likely pathology in a condition in which the majority of individuals will not have major complications.

**Self-help websites for HHT families**

Country and language-specific information for HHT patients and families is available through a number of websites. The EuroHHT consortium plans an umbrella entry European website for 2009.

<table>
<thead>
<tr>
<th>Country</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denmark</td>
<td><a href="http://www.osler.dk">http://www.osler.dk</a></td>
</tr>
<tr>
<td>France</td>
<td><a href="http://www.amro-france.org">http://www.amro-france.org</a></td>
</tr>
<tr>
<td>Germany</td>
<td><a href="http://www.morbus-osler.de">http://www.morbus-osler.de</a></td>
</tr>
<tr>
<td>Ireland</td>
<td><a href="http://www.gracenolan.com">http://www.gracenolan.com</a></td>
</tr>
<tr>
<td>Italy</td>
<td><a href="http://www.hht.it">http://www.hht.it</a></td>
</tr>
<tr>
<td>Netherlands</td>
<td><a href="http://www.renduoslerweber.nl">http://www.renduoslerweber.nl</a></td>
</tr>
<tr>
<td>Spain</td>
<td><a href="http://www.asociacionhht.org">http://www.asociacionhht.org</a></td>
</tr>
<tr>
<td>UK</td>
<td><a href="http://www.telangiectasia.co.uk">http://www.telangiectasia.co.uk</a></td>
</tr>
<tr>
<td>USA and international</td>
<td><a href="http://www.hht.org">http://www.hht.org</a></td>
</tr>
</tbody>
</table>

**Acknowledgements**

We thank Jamie McDonald (US), Elisabetta Buscarini (Italy), Kees Westermann (Netherlands) and Roberto Zarrabezitia (Spain) for reviewing and commenting on the paper; medical members of the EuroHHT consortium for helpful discussions including approval of the highlighted (*) statements by Gregor Bachmann-Harrildstad (Norway), Elisabetta Buscarini (Italy), Sophie Dupuis-Girod (France), Anette Kjeldsen (Denmark), Pascal Lacombe (France), Henri Plauchu (France), Carlo Sabba (Italy), Kees Westermann (Netherlands) and Roberto Zarrabezitia (Spain); for specific pulmonary and neurovascular discussions, James Jackson (UK) and Pierre Lasjaunias (France); and for approval of paediatric statements, Nicky Coote (UK) and Andrew Bush (UK). FSG is supported by a British Heart Foundation PhD studentship. CLS is grateful for support from the NIHR Biomedical Research Centre Funding Scheme, and thanks the British HHT families, whose donations have supported HHT clinical research at the Hammersmith Hospital.

**References**


40 Derynck R, Zhang YE: Smad-dependent and Smad-independent components of the endothelial transforming growth factor beta 1 with higher affinity receptors and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 2005; 204: 574–584.


47 Pece-Barbara N, Vear S, Kathirk amathamby K et al: Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor beta 1 with higher affinity receptors and an activated ALK1 pathway. J Biol Chem 2005; 280: 27800–27808.

48 Daly AC, Randall RA, Hill CS: Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated...


